Company: SHPH
Filing Date: 2025-04-21
Form Type: DEFR14A
Source: 0001641172-25-005474
Chunk: 13

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-04-21
Form: DEFR14A
Chunk 13
---
 required to be discussed by the statement on Auditing Standards No.            
 61, as amended.                                                                                                                       |
| ● | Reviews                                                                                                                               
 written disclosures and letters from the independent accountant required by applicable requirements of the Public Company Accounting  
 Oversight Board, or the PCAOB, regarding the independent accountant’s communications with the Audit Committee concerning independence 
 and discusses with the independent accountant the independent accountant’s independence.                                              |
| ● | Based                                                                                                                                 
 on the review and discussions with the Company’s independent accountant, recommends to the Board of Directors that such audited       
 financial statements and unaudited interim financial statements be included in the Company’s annual report on Form 10–K               
 and quarterly reports on Form 10-Q, respectively, for the applicable periods for filing with the SEC.                                 |

COMPENSATION Committee

| MEMBERS         |     | MEETINGS               
 HELD IN 2024: 0*       
 ACTIONS                
 BY WRITTEN CONSENT: 2* |
| George          
 Scorsis (Chair) 
 Steven          
 Richards        
 Oleh            
 Nabyt           |     |                        |

* Messrs. Scorsis and Nabyt joined as the Company’s Board in February 2025. Accordingly, our previous Compensation Committee members took action by written consent for the Compensation Committee in 2024 until their resignations in February 2025.

KEY RESPONSIBILITIES

| ● | Makes                                                                                                                                  
 recommendations to the Board of Directors concerning the salaries and incentive compensation for our officers, including our principal 
 executive officer and employees and administers our stock option plan.                                                                 |

NOMINATING AND CORPORATE GOVERNANCE Committee

| MEMBERS      |     | MEETINGS               
 HELD IN 2024: 0*       
 ACTIONS                
 BY WRITTEN CONSENT: 0* |
| Joseph       
 Tung (Chair) |     |                        |
| George       
 Scorsis      |     |                        |
| Oleh         
 Nabyt        |     |                        |

* Messrs. Tung, Scorsis and Nabyt joined as the Company’s Board in February 2025. Accordingly, our previous Nominating and Corporate Governance Committee members took action by written consent for the Nominating and Corporate Governance Committee in 2024 until their resignations in February 2025.

KEY RESPONSIBILITIES

| ● | Assists                                                                                                                          
 the Board of Directors in identifying qualified individuals to become board members, in determining the composition of the Board 
 of Directors and in